{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:59:22Z","timestamp":1780567162963,"version":"3.54.1"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The aim of this study was to characterize and validate the population pharmacokinetics of gentamicin in infants and to determine the influences of clinically relevant covariates to explain the inter- and intraindividual variabilities associated with this drug. Infants receiving intravenous gentamicin and with routine therapeutic drug monitoring were consecutively enrolled in the study. Plasma concentration and time data were retrospectively collected from 208 infants (1 to 24 months old) of the Hospital Universitario Severo Ochoa (Spain), of whom 44% were males (mean age [\u00b1 standard deviation], 5.8 \u00b1 4.8 months; mean body weight, 6.4 \u00b1 2.2 kg). Data analysis was performed with NONMEM 7.2. One- and two-compartment open models were analyzed to estimate the gentamicin population parameters and the influences of several covariates. External validation was carried out in another population of 55 infants. The behavior of gentamicin in infants exhibits two-compartment pharmacokinetics, with total body weight being the covariate that mainly influences central volume (\n            <jats:italic>V<\/jats:italic>\n            <jats:sub>c<\/jats:sub>\n            ) and clearance (CL); this parameter was also related to creatinine clearance. Both parameters are age related and different from those reported for neonatal populations. On the basis of clinical presentation and diagnosis, a once-daily dosage regimen of 7 mg\/kg of body weight every 24 h is proposed for intravenous gentamicin, followed by therapeutic drug monitoring in order to avoid toxicity and ensure efficacy with minimal blood sampling. Gentamicin pharmacokinetics and disposition were accurately characterized in this pediatric population (infants), with the parameters obtained being different from those reported for neonates and children. These differences should be considered in the dosing and therapeutic monitoring of this antibiotic.\n          <\/jats:p>","DOI":"10.1128\/aac.03464-14","type":"journal-article","created":{"date-parts":[[2014,11,11]],"date-time":"2014-11-11T05:42:42Z","timestamp":1415684562000},"page":"482-489","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":22,"title":["Population Pharmacokinetics of Gentamicin and Dosing Optimization for Infants"],"prefix":"10.1128","volume":"59","author":[{"given":"Susanna E.","family":"Medell\u00edn-Garibay","sequence":"first","affiliation":[{"name":"Departamento de Farmacia, Facultad de Ciencias Qu\u00edmicas, Universidad Aut\u00f3noma de San Luis Potos\u00ed, San Luis Potos\u00ed, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A\u00edda","family":"Rueda-Naharro","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, Hospital Universitario Severo Ochoa, Legan\u00e9s, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Pe\u00f1a-Cabia","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, Hospital Universitario Severo Ochoa, Legan\u00e9s, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benito","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, Hospital Universitario Severo Ochoa, Legan\u00e9s, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Romano-Moreno","sequence":"additional","affiliation":[{"name":"Departamento de Farmacia, Facultad de Ciencias Qu\u00edmicas, Universidad Aut\u00f3noma de San Luis Potos\u00ed, San Luis Potos\u00ed, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Barcia","sequence":"additional","affiliation":[{"name":"Departamento de Farmacia y Tecnolog\u00eda Farmac\u00e9utica, Universidad Complutense de Madrid, Plaza de Ram\u00f3n y Cajal, Ciudad Universitaria, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000012"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2165\/00003495-199447060-00004","article-title":"Parenteral aminoglycoside therapy. Selection, administration and monitoring","volume":"47","author":"Kumana CR","year":"1994","unstructured":"Kumana CR, Yuen KY. 1994. Parenteral aminoglycoside therapy. Selection, administration and monitoring. Drugs 47:902\u2013913.","journal-title":"Drugs"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOO.0b013e32833e05ec"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/937861"},{"key":"e_1_3_2_6_2","first-page":"307","volume-title":"Principles and practice of infectious diseases","author":"Gilbert DN","year":"2005","unstructured":"Gilbert DN. 2005. Aminoglycosides, p 307\u2013336. In Mandell GL, Bennett JE, Dolin R (ed), Principles and practice of infectious diseases, 6th ed. Churchill Livingstone, New York, NY.","edition":"6"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.132.3.253"},{"key":"e_1_3_2_8_2","volume-title":"p 787\u2013790, The pediatric & neonatal dosage handbook","author":"Taketomo CK","year":"2013","unstructured":"Taketomo CK, Hodding JH, Kraus DM. 2013. p 787\u2013790, The pediatric & neonatal dosage handbook, 20th ed. Leximcomp, Hundson, OH.","edition":"20"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.24.25"},{"key":"e_1_3_2_10_2","volume-title":"Guidance for industry: general considerations for pediatric pharmacokinetic studies for drugs and biological products","author":"U.S. FDA","year":"1998","unstructured":"U.S. FDA. 1998. Guidance for industry: general considerations for pediatric pharmacokinetic studies for drugs and biological products. U.S. Food and Drug Administration, Silver Spring, MD. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm072114.pdf."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.6.680"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200948020-00001"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1289\/ehp.94102s11107","article-title":"Pharmacokinetics in the infant","volume":"102","author":"Milsap RL","year":"1994","unstructured":"Milsap RL, Jusko WJ. 1994. Pharmacokinetics in the infant. Environ Health Perspect 102(Suppl 11):S107\u2013S110.","journal-title":"Environ Health Perspect"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31821e405d"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.114.1.e111"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2005.12.001"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R029"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(03)00057-6"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.14"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-012-0015-8"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.58.2.259"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.5.1115"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.4"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01060893"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470087978.ch8"},{"key":"e_1_3_2_26_2","volume-title":"WHO child growth standards: Length\/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development","author":"World Health Organization","year":"2006","unstructured":"World Health Organization. 2006. WHO child growth standards: Length\/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/childgrowth\/standards\/Technical_report.pdf?ua=1."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0782-9"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2003.07.010"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl244"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/43.1.222"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200112000-00016"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3468(98)90540-1"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128072-200204070-00005"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03464-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03464-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:54:17Z","timestamp":1645484057000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.03464-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1128\/AAC.03464-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.03464-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"2014-07-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-12-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}